Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial

worldpharmanewsJuly 21, 2020

Tag: AZD1222 , COVID-19 vaccine , COV001 , SARS-CoV-2

PharmaSources Customer Service